Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dean F Bajorin

Showing results (111-120 of 169) with videos related to

Pageof 17
Sort By:
Plos Medicine|May 30, 2017
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysisAlexandra Snyder, Tavi Nathanson, Samuel A Funt, et al.
The American Journal of Surgical Pathology|May 29, 2019
PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available AntibodiesHenning Reis, Rene Serrette, Jennifer Posada, et al.
Clinical Genitourinary Cancer|January 1, 2018
Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder CancerLauren C Harshman, Abhishek Tripathi, Matthew Kaag, et al.
Cancer|August 2, 2016
Genomic characterization of response to chemoradiation in urothelial bladder cancerNeil B Desai, Sasinya N Scott, Emily C Zabor, et al.
The New England Journal of Medicine|February 18, 2017
Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaJoaquim Bellmunt, Ronald de Wit, David J Vaughn, et al.
The Journal of Urology|June 20, 2020
Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 InhibitorsGuru Sonpavde, Juliane Manitz, Chen Gao, et al.
Human Pathology|March 31, 2018
Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinomaSumit Isharwal, Hongying Huang, Gouri Nanjangud, et al.
Clinical Genitourinary Cancer|December 3, 2014
Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinomaGuru Sonpavde, Gregory R Pond, Jonathan E Rosenberg, et al.
Urology Practice|February 5, 2024
Changes in the Perioperative Management and Outcomes of Patients With Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy at Memorial Sloan Kettering Cancer Center: Over 20 Years of ExperienceWesley Yip, Melissa J Assel, Nathan C Wong, et al.
European Urology|August 6, 2014
Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladderPhilip H Kim, Eugene K Cha, John P Sfakianos, et al.
Pageof 17

Showing results (111-120 of 169) with videos related to

Sort By:
Pageof 17
Plos Medicine|May 30, 2017
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysisAlexandra Snyder, Tavi Nathanson, Samuel A Funt, et al.
The American Journal of Surgical Pathology|May 29, 2019
PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available AntibodiesHenning Reis, Rene Serrette, Jennifer Posada, et al.
Clinical Genitourinary Cancer|January 1, 2018
Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder CancerLauren C Harshman, Abhishek Tripathi, Matthew Kaag, et al.
Cancer|August 2, 2016
Genomic characterization of response to chemoradiation in urothelial bladder cancerNeil B Desai, Sasinya N Scott, Emily C Zabor, et al.
The New England Journal of Medicine|February 18, 2017
Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaJoaquim Bellmunt, Ronald de Wit, David J Vaughn, et al.
The Journal of Urology|June 20, 2020
Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 InhibitorsGuru Sonpavde, Juliane Manitz, Chen Gao, et al.
Human Pathology|March 31, 2018
Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinomaSumit Isharwal, Hongying Huang, Gouri Nanjangud, et al.
Clinical Genitourinary Cancer|December 3, 2014
Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinomaGuru Sonpavde, Gregory R Pond, Jonathan E Rosenberg, et al.
Urology Practice|February 5, 2024
Changes in the Perioperative Management and Outcomes of Patients With Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy at Memorial Sloan Kettering Cancer Center: Over 20 Years of ExperienceWesley Yip, Melissa J Assel, Nathan C Wong, et al.
European Urology|August 6, 2014
Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladderPhilip H Kim, Eugene K Cha, John P Sfakianos, et al.
Pageof 17